Literature DB >> 18477890

Differential expression of heat shock protein 105 in melanoma and melanocytic naevi.

Faith Chengetayi Muchemwa1, Tetsuya Nakatsura, Satoshi Fukushima, Yasuharu Nishimura, Toshiro Kageshita, Hironobu Ihn.   

Abstract

The objective of this study is to assess the expression of heat shock protein 105 (HSP105) in melanoma and benign melanocytic lesions. The expression of HSP105 in 62 human melanoma samples--46 primary and 16 metastatic lesions--and 42 melanocytic naevi samples, was assessed by immunohistochemistry. Western blotting was performed on melanoma cell lines, melanoma tissues with matched normal skin and melanocytic naevi. The Mann-Whitney test was used for statistical analysis and significance was considered to be P less than 0.05. Seventy-four per cent of the primary melanoma lesions and 88% of the metastatic lesions overexpressed HSP105 by immunohistochemistry. The majority of melanocytic lesions (95%) were negative (P<0.05). Western blotting detected high expression of HSP105 in melanoma cell lines and tissues. The expression of HSP105 was related to the invasiveness of the lesions. Melanocytic naevi expressed HSP105 at a level that was similar to that of normal skin. Our results show that high expression of HSP105 is associated with malignant melanoma especially advanced and metastatic lesions. The results suggest that HSP105 analysis may be a helpful tool as a poor prognostic indicator and as a diagnostic aid in problematic lesions; in addition, melanoma can be included in the growing list of tumours overexpressing HSP105 to be targeted for potential HSP105-based therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18477890     DOI: 10.1097/CMR.0b013e3282fe9a16

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  9 in total

Review 1.  High molecular weight stress proteins: Identification, cloning and utilisation in cancer immunotherapy.

Authors:  Xiang-Yang Wang; John R Subjeck
Journal:  Int J Hyperthermia       Date:  2013-07-05       Impact factor: 3.914

Review 2.  Molecular physiology of SPAK and OSR1: two Ste20-related protein kinases regulating ion transport.

Authors:  Kenneth B Gagnon; Eric Delpire
Journal:  Physiol Rev       Date:  2012-10       Impact factor: 37.312

Review 3.  Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update.

Authors:  Daniel R Ciocca; Andre Patrick Arrigo; Stuart K Calderwood
Journal:  Arch Toxicol       Date:  2012-08-11       Impact factor: 5.153

4.  A 781-kb deletion of 13q12.3 in a patient with Peters plus syndrome.

Authors:  Chad R Haldeman-Englert; Taiyabah Naeem; Elizabeth A Geiger; Ashley Warnock; Holly Feret; Melissa Ciano; Stefanie L Davidson; Matthew A Deardorff; Elaine H Zackai; Tamim H Shaikh
Journal:  Am J Med Genet A       Date:  2009-08       Impact factor: 2.802

5.  Immunohistochemistry: relevance in dermatology.

Authors:  Aparna Palit; Arun C Inamadar
Journal:  Indian J Dermatol       Date:  2011-11       Impact factor: 1.494

Review 6.  Heat shock proteins in multiple myeloma.

Authors:  Lei Zhang; Jacqueline H L Fok; Faith E Davies
Journal:  Oncotarget       Date:  2014-03-15

Review 7.  Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach.

Authors:  Suman Chatterjee; Timothy F Burns
Journal:  Int J Mol Sci       Date:  2017-09-15       Impact factor: 5.923

8.  Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial.

Authors:  Yasuhiro Shimizu; Toshiaki Yoshikawa; Takashi Kojima; Kayoko Shoda; Kazuto Nosaka; Shoichi Mizuno; Satoshi Wada; Yuki Fujimoto; Tetsuro Sasada; Kenichi Kohashi; Hideaki Bando; Itaru Endo; Tetsuya Nakatsura
Journal:  Cancer Sci       Date:  2019-09-19       Impact factor: 6.716

Review 9.  The Role of Non-Canonical Hsp70s (Hsp110/Grp170) in Cancer.

Authors:  Graham Chakafana; Addmore Shonhai
Journal:  Cells       Date:  2021-01-28       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.